Five things for pharma marketers to know: Monday, August 7, 2017

Share this content:


1. Some insurers are denying access to generic versions of prescribed drugs, most likely due to the fact that drugmakers are making deals with them to ensure that their brand-name drugs are covered. (ProPublica and The New York Times)

2. In related news, the generic version of Mylan's EpiPen is costing some consumers more than the branded version. (WSJ)

3. Teva Pharmaceutical Industries plans to lay off 7,000 employees and close 15 plants over the next two years, citing lower than expected second-quarter results for 2017. (Philadelphia magazine)

4. Martin Shkreli, the former pharma CEO best known for raising the price of Daraprim from $13.50 to $750, has been found guilty of securities fraud. The pricing decision put the so-called “pharma bro” in the national spotlight. (AP via WaPo)

5. UnitedHealthcare reversed a decision that denied coverage of Gilead Sciences' Truvada for pre-exposure prophylaxis due to the patient's “high-risk homosexual behavior.” The FDA-approved indication for the drug is high-risk sexual behavior. (NBC)

Share this content:
Scroll down to see the next article